Edwards Lifesciences. Patient-Focused Innovations for Structural Heart Disease and Critical Care Monitoring
|
|
- Jodie Hodge
- 5 years ago
- Views:
Transcription
1 Edwards Lifesciences Patient-Focused Innovations for Structural Heart Disease and Critical Care Monitoring
2 Use of Non-GAAP Financial Measures Unless otherwise indicated, all figures are GAAP financial measures The Company uses the term underlying when referring to non-gaap sales information, which excludes discontinued and acquired products, foreign exchange fluctuations, and the THVT sales return reserves and excluding special items and adjusted net income and adjusted EPS to also exclude gains and losses from special items such as significant investments, litigation, amortization and business development transactions. A reconciliation of non-gaap historical financial measures to the most comparable GAAP measure is available at The Company is not able to provide a reconciliation of future projections that exclude special items to expected reported results due to the unknown effect, timing and potential significance of special charges or gains, and management s inability to forecast charges associated with future transactions and initiatives 1/11/16 2
3 Cautionary Statement Presentations and comments made today by the management of Edwards Lifesciences Corporation will include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of These forward-looking statements can sometimes be identified by the use of words such as may, will, should, anticipate, believe, plan, project, estimate, expect, intend, guidance, outlook, optimistic, aspire, confident or other forms of these words or similar expressions. These may include, but are not limited to, the company s financial goals or expectations for 2016 and beyond; expectations for new products and the global TAVR opportunity; the timing and results of clinical trials and regulatory approvals; and opportunities for growth. Forward-looking statements are based on estimates and assumptions made by management of the company and are believed to be reasonable, though they are inherently uncertain and difficult to predict. Our forward-looking statements speak only as of the date on which they are made and we do not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of the statement. If the Company does update or correct one or more of these statements, investors and others should not conclude that the company will make additional updates or corrections. Forward-looking statements involve risks and uncertainties that could cause actual results or experience to differ materially from that expressed or implied by the forward-looking statements. Factors that could cause actual results or experience to differ materially from that expressed or implied by the forward looking statements are detailed in the company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, These filings, along with important safety information about our products, may be found at edwards.com. 1/11/16 3
4 Driven by a Passion to Help Patients Edwards partners with clinicians to develop innovative technologies in the areas of structural heart disease and critical care monitoring that enable them to save and enhance lives. 1/11/16 4
5 Global Leadership Over 95% of sales from products in #1 global positions Serving patients in more than 100 countries worldwide Surgical Heart Valve Therapy Critical Care Surgical Heart Valve Therapy Critical Care Transcatheter Heart Valve Therapy Japan ROW Europe U.S. THVT E 1/11/16 5
6 Edwards Strategy Patient-Centric Focused Innovation Industry Leadership Fulfilling unmet needs of structural heart and critically ill patients Transforming care drives enduring value creation Breakthrough therapies with superior clinical and economic evidence Active product portfolio management Pioneering legacy of establishing standards of care Trusted relationships with clinicians, payors and regulators Create Value with Therapies that Transform Patient Care 1/11/16 6
7 Industry Leadership 1/11/16 7
8 Edwards is Well Positioned to Maintain Global TAVR Leadership A beating heart alternative to traditional surgery for high risk aortic stenosis patients An increasing body of evidence is changing the treatment of aortic stenosis SAPIEN 3 has delivered superior clinical outcomes Continuing to build robust clinical evidence to expand patient access Investing to be the technology leader 1/11/16 8
9 Global TAVR Opportunity Could Exceed $5B in 2021 Observations For Severe, Symptomatic AS Patients Age plays a significant role in the diagnosis and treatment of aortic stenosis Additional risk factors not captured in STS score become more important with patient age Patients 14,000 12,000 10,000 8,000 SAVR TAVR 2015 Severe Symptomatic AS Patients in the U.S. 1 Untreated (estimated) A safe interventional procedure has the potential to lift treatment rates in older age group 6,000 4,000 2, Age (1) Nkomo 2006, Iivanainen 1996, Aronow 1991, Bach 2007, Freed 2010, Iung 2007, Pellikka 2005, Brown 2008, Thourani 2015, internal estimates. 1/11/16 9
10 Positive Outcomes and Expanded Indications Should Encourage Untreated Patients to Seek Therapy Intermediate Risk Low Risk Trial Early Trial Design Variables PARTNER II results expected to enable intermediate risk patient access Expect U.S. approval in late 2016 Intermediate Risk Low Risk Low risk: STS 0 to 4/5 Randomized 1:1 to surgery TAVR for tissue valve candidate High Risk Expect to start U.S. trial in /11/16 10
11 The Edwards SAPIEN 3 Ultra System Further Streamlines the TAVR Procedure The Edwards SAPIEN 3 Ultra System On-balloon delivery system Next-generation sheath CE Mark approval expected in Q Significant progress on Pulmonic indication expected in 2016 CENTERA design expected to be best-in-class self-expanding platform; CE Mark anticipated in 2H 2017 Pursuing indication expansion utilizing current platforms Edwards SAPIEN 3 Ultra System The Edwards SAPIEN 3 Ultra System and CENTERA are not approved for sale. 1/11/16 11
12 The Leader in a ~$1.8B Global Surgical Heart Valve Segment Differentiated, long-term evidence and highly trusted brand More long-term clinical publications than any other surgical valve Surgical AVR expected to continue to be the gold standard for younger patients and complex procedures Innovation planned beyond aortics, expanding treatment options in other valve positions Strategy is to differentiate surgical offerings with superior clinical and health economic evidence 1/11/16 12
13 INTUITY and INSPIRIS Should Extend Our Leadership in Surgical Valves EDWARDS INTUITY Elite Facilitates MIS AVR Trusted platform, rapid deployment, and smaller incision U.S. launch expected mid-2016 INSPIRIS RESILIA tissue has demonstrated reduced calcification 1 and improved hemodynamics VFit technology could improve hemodynamics following future TAVR valve-in-valve procedure EU and U.S. launches anticipated in 2017 INTUITY not approved for sale in the U.S. INSPIRIS not approved for sale. (1) Flameng W, et al. J Thorac Cardiovasc Surg. 2015;149: /11/16 13
14 Edwards Unmatched Portfolio of Market Leading Hemodynamic Products is a Competitive Advantage Core Hemodynamic Products Enhanced Surgical Recovery Products TruWave Transducers Swan-Ganz Pulmonary Artery Catheter EV1000 Clinical Platform FloTrac Sensor ClearSight Finger Cuff 1/11/16 14
15 Enhanced Surgical Recovery is an Underpenetrated Global Opportunity Enhanced surgical recovery is focused on reducing complications and length of stay ClearSight noninvasive sensor expands benefits of ESR to a broader patient population Innovating to drive future ESR growth Next generation hemodynamic monitor Integrated semi-closed loop system for standardized management of patient fluid levels Large Opportunity Exists to Reduce Complications from Surgery Unpenetrated $550M Penetrated $150M Size of ESR Opportunity 1/11/16 15
16 Innovation Fuels Long-Term Growth 1/11/16 16
17 Edwards is Investing Aggressively to Lead Transformational Structural Heart Therapies Selected Programs Description Adjacent Valves Heart Failure CardiAQ-Edwards FMR Program Harpoon FORMA CardioKinetix HF Programs Mitral Replacement Functional Mitral Repair Degenerative Mitral Repair Tricuspid Repair LV Reduction LV Restoration 1/11/16 17
18 Combined CardiAQ-Edwards Platform Can Drive Leadership Focus on building clinical experience in TMVR CardiAQ platform complements the FORTIS program One valve, multiple delivery systems Unique anchoring mechanism Early patient experience is encouraging An integrated, dedicated team Planned clinical timelines: CE Mark trial to begin mid-2016 U.S. EFS enrollment to start soon Near-term product additions: Lower valve profile, additional valve sizes, delivery system improvements, Edwards tissue The CardiAQ-Edwards valve is not available for sale. 1/11/16 18
19 Other Structural Heart Initiatives Focused on Significant Unmet Patient Needs FORMA Harpoon CardioKinetix Implantable spacer that reduces regurgitant tricuspid flow 1.6M U.S. patients suffer from moderate-to-severe TR 1 Early human clinical experience is promising CE Mark trial and U.S. EFS to begin in 2016 Transcatheter approach to chordal repair 1.6M U.S. patients years old 2 Investment and option to acquire Harpoon Medical Expect to begin CE Mark enrollment early 2016 Treatment for left ventricular dysfunction 1.4M U.S. Class III patients underserved 3 Investment and option to acquire CardioKinetix U.S. pivotal trial 50% enrolled; CE Mark as of 2011 (1) Stuge and Liddicoat. Emerging opportunities for cardiac surgeons within structural heart disease. J Thorac Cardio Surg 2006;132: (2) Singh et al., Prevalence and Clinical Determinants of MR (Framingham), Am J Cardiology 1999 (3) IMPROVE-HF Registry, Nursing Home Survey 2004, NHANES , CVRG FORMA, Harpoon and CardioKinetix are not available for sale. 1/11/16 19
20 Financial Highlights 1/11/16 20
21 Edwards is an Attractive Investment Strong organic topline growth Disciplined SG&A expense control Successful long-term track record Robust free cash flow Commitment to returning capital to shareholders Net Sales ($ in billions and underlying growth rates) 11% 13% ~15% 7-11% $1.90 $2.05 $2.32 $ $ E 2016E Guidance provided on 12/9/15; Actual results to be reported on 2/2/16 1/11/16 21
22 2016 Guidance (Excludes special items) ($ in millions, except EPS) 2016 Guidance Total Net Sales $2,500 - $2,750 Gross Profit Margin 74% - 75% Free Cash Flow $400- $440 EPS $ $2.40 1/11/16 22
23 Edwards is Poised for Long-Term Success Patient-centric culture Leading edge research and development Industry leading competitive positions Trusted relationships with clinicians, regulators and payors globally Strong geographic diversification Nimble, adaptive business model Focused strategy to deliver patient benefit and shareholder value 1/11/16 23
24
Edwards Lifesciences. Patient-Focused Innovations for Structural Heart Disease and Critical Care Monitoring
Edwards Lifesciences Patient-Focused Innovations for Structural Heart Disease and Critical Care Monitoring Cautionary Statement Presentations and comments made today by the management of Edwards Lifesciences
More informationTranscatheter Heart Valve Therapy
Edwards Lifesciences 2017 Investor Conference Transcatheter Heart Valve Therapy Larry L. Wood Corporate Vice President, Transcatheter Heart Valves Leader in ~$3B Global Transcatheter Heart Valves Primary
More informationCritical Care. Building Future Growth with Innovation. Katie M. Szyman Corporate Vice President, Critical Care
Katie M. Szyman Corporate Vice President, Building Future Growth with Innovation Products Benefit Millions of Patients per Year Our new HemoSphere capital platform strengthens our core portfolio We are
More informationTranscatheter Aortic Valve Replacement. Larry L. Wood Corporate Vice President
Transcatheter Aortic Valve Replacement Larry L. Wood Corporate Vice President Leader in ~$3.5B Global Transcatheter Aortic Valve Replacement Market Primary global growth drivers: indication expansion,
More informationTranscatheter Mitral & Tricuspid Therapies. Bernard J. Zovighian Corporate Vice President
Transcatheter Mitral & Tricuspid Therapies Bernard J. Zovighian Corporate Vice President We Will Lead and Transform Treatment for Patients with Mitral and Tricuspid Diseases Mitral and Tricuspid Diseases
More informationTranscatheter Mitral and Tricuspid Therapies
Edwards Lifesciences 2017 Investor Conference Transcatheter Mitral and Tricuspid Therapies Donald E. Bobo, Jr. Corporate Vice President, Strategy & Corporate Development Edwards is Poised to Lead the Transcatheter
More informationLivaNova Investor Day
LivaNova Investor Day TRANSCATHETER MITRAL VALVE REPLACEMENT (TMVR) Paul Buckman General Manager, TMVR September 14, 2017 Safe Harbor Statement Certain statements in this presentation, other than purely
More informationST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015
ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation
More informationJanuary 30, 2018 Dow Wilson President and Chief Executive Officer
Acquisition of SIRTeX January 30, 2018 Dow Wilson President and Chief Executive Officer This presentation is intended exclusively for investors. It is not intended for use in Sales or Marketing. Forward-Looking
More informationBoston Scientific is advancing...
Boston Scientific is advancing... Our mission Our values Boston Scientific is dedicated to transforming lives through innovative Caring Meaningful Innovation High Performance medical solutions that improve
More informationEdwards Lifesciences 2011 Investor Conference 12/9/2011
Edwards Lifesciences 2011 Investor Conference EDWARDS LIFESCIENCES Transcatheter Heart Valves Larry L. Wood Corporate Vice President, Transcatheter Valve Replacement 2 1 Edwards Lifesciences 2011 Investor
More informationPATENCY-1 Top-Line Results
PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,
More informationPutting ALK on the right growth trajectory
Putting ALK on the right growth trajectory Økonomisk Ugebrevs Kapitalmarkedseftermiddag 15. marts 2018 Per Plotnikof, VP Corporate Communications and IR Marts 2018 Allergy: a global disease with a large
More informationStraumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America
Media release Straumann s net revenues reach CHF 185 million in Q1, driven by continuing double-digit growth in America Group net revenue rises 2% (l.c.) as double-digit increases across America offset
More informationRevolutionizing how advanced heart disease is treated
LEERINK Partners 5th Annual Healthcare Conference Revolutionizing how advanced heart disease is treated NASDAQ: NCVN, TSX: NVC Alexei Marko, CEO February 2016 Forward-Looking Statements Statements contained
More informationNASDAQ: ELGX December Innovation that Empowers
NASDAQ: ELGX www.endologix.com December 2014 Innovation that Empowers Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act
More informationRevolutionizing how advanced heart disease is treated. Alexei Marko, CEO Chris Clark, CFO November 2014
Revolutionizing how advanced heart disease is treated Alexei Marko, CEO Chris Clark, CFO November 2014 Forward-Looking Statements Statements contained herein that are not based on historical or current
More informationADM to Acquire Neovia and Probiotics International Limited. July 2, 2018
ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates
More informationSlide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A
Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or
More informationSecond Quarter and First Half 2011 Conference Call. 29 July, SORIN GROUP Presentation 1
Second Quarter and First Half 2011 Conference Call 29 July, 2011 SORIN GROUP Presentation 1 DISCLAIMER This presentation contains management preliminary estimates and forward-looking statements, including
More informationCompany Overview February 26, 2019
Company Overview February 26, 2019 SAFE HARBOR Cautionary Note Regarding Forward-Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationCredit Suisse 27 th Annual Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE Credit Suisse 27 th Annual Healthcare Conference November 14, 2018 Forward-Looking Statements and Adjusted Financial Information This
More informationEdwards Lifesciences 2012 Investor Conference 12/4/2012
Carlyn D. Solomon Corporate Vice President, Critical Care Executive Summary Edwards is extending its leadership in global hemodynamic monitoring We expect continued growth of our gold standard products,
More informationValue creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO
Value creation through profitable growth Danske Bank Winter Seminar 2017, Copenhagen Lars Rasmussen, President & CEO Forward-looking statements The forward-looking statements contained in this presentation,
More informationDIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM
November 28, 2017 DIEBOLD NIXDORF AG AT GERMANY EQUITY FORUM Dr. Jürgen Wunram Agenda Diebold Nixdorf AG History and shareholder structure Market trends, strategy and progress of integration Diebold Nixdorf
More informationResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference
ResMed Inc. 36 th Annual J.P. Morgan Healthcare Conference Mick Farrell CEO January 8, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking
More informationTAVR in 2020: What is Next!!!!
TAVR in 2020: What is Next!!!! Vinod H. Thourani, MD Professor of Surgery Chairman, Department of Cardiac Surgery Medstar Heart and Vascular Institute Washington Hospital Center Washington, DC Disclosures
More informationAcquisition of Novartis Influenza Vaccines Business. 27 th October 2014
1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include
More informationValue creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO
Value creation through profitable growth Handelsbanken Nordic Large Cap Seminar, Stockholm 2016 Anders Lonning-Skovgaard, CFO Coloplast has four business areas all with global sales presence Group revenue
More informationGenomic Health. Kim Popovits, Chairman, CEO and President
Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and
More informationIpsen Acquisition of Clementia Pharmaceuticals. February 25, 2019
Ipsen Acquisition of Clementia Pharmaceuticals February 25, 2019 Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements,
More informationCorporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015
(Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation
More informationPositioned for Growth
Positioned for Growth Annual Shareholders Meeting July 21, 2016 Paris Panayiotopoulos President and Chief Executive Officer David Sachs Non small cell lung cancer ARIAD clinical trial patient This presentation
More informationSolutions For The Aging Spine
Solutions For The Aging Spine NASDAQ: ATEC February 2009 www.alphatecspine.com Slide 0 5818 El Camino Real, Carlsbad, CA 92008 www.alphatecspine.com Forward Looking Statements This presentation and our
More informationInvestor Presentation. Q April 26, 2018
Investor Presentation Q3 2018 April 26, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities
More informationPercutaneous Valve Interventions. Percutaneous Valve Interventions
Percutaneous Valve Interventions Stanton J. Rowe President, Percutaneous Valve Interventions Edwards is Best Positioned to Capitalize on Percutaneous Valve Opportunities #1 global valve replacement and
More informationWhat is TAVR? Transcatheter Aortic Valve Replacement
What is TAVR? Transcatheter Aortic Valve Replacement What Are Your Options for Treating Severe Aortic Stenosis? Treatment for aortic stenosis depends on how far your disease has progressed. If your stenosis
More informationNeovasc Inc. Alexei Marko, CEO. January 2012 OneMedForum
Neovasc Inc. Alexei Marko, CEO January 2012 OneMedForum 2 Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements
More informationNext Generation Therapies: Aortic, Mitral and Beyond
Next Generation Therapies: Aortic, Mitral and Beyond Scott M Lilly, MD PhD Medical (Interventional) Director, Structural Heart Program Heart Summit, Lima OH August 26 th, 2017 Next Generation Therapies:
More informationMedSurg: Endoscopy Presentation for the Investment Community at DDW. Art Butcher Senior Vice President and President, Endoscopy
MedSurg: Endoscopy Presentation for the Investment Community at DDW Art Butcher Senior Vice President and President, Endoscopy Safe Harbor for Forward-Looking Statements This presentation contains forward-looking
More informationTranscatheter Mitral Valve Replacement How Close Are We?
Transcatheter Mitral Valve Replacement How Close Are We? Gregory Pavlides, MD, PhD, FACC, FESC Professor of Medicine Miscia Chair of Interventional Cardiology Director, Cardiac Catheterization Laboratories,
More informationSorin Group. Marco Chiadò Piat, VP Corporate Development. Goldman Sachs European Medtech and Healthcare Services 5-6 September 2007
Sorin Group Marco Chiadò Piat, VP Corporate Development Goldman Sachs European Medtech and Healthcare Services 5-6 September 2007 Sorin FY 2006 results by Business Area FY 06 ( Mn) FY 06 vs FY 05 as reported
More informationADAPTIMMUNE INVESTOR PRESENTATION. August 2016
ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
More informationNatus Medical Incorporated. Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017
Natus Medical Incorporated Jeffries Global Healthcare CONFERENCE Tuesday June 6, 2017 Forward-Looking Statements This presentation contains forward-looking statements including statements regarding our
More informationUSPSTF Draft Recommendations Investor Call. October 6, 2015
USPSTF Draft Recommendations Investor Call October 6, 2015 v Safe Harbor Statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the
More informationFirst Albany Orthopedics Conference Marina Village, San Diego February 13, 2007 Orthofix International
First Albany Orthopedics Conference Marina Village, San Diego February 13, 2007 Orthofix International Tom Hein, CFO Safe Harbor Statement Except for historical information contained herein, the statements
More informationTranscatheter Valve Replacement: Current State in 2017
Transcatheter Valve Replacement: Current State in 2017 Marc A. Sintek MD Assistant Professor of Medicine Interventional Cardiology Cardiovascular Division Washington University in St. Louis Missouri ACP
More informationCountry Coverage. Company Coverage
Global Heart Valve Devices Market: Analysis By Procedure (Replacement & Repair), Replacement Procedure By Technique (Mechanical, Bioprosthetic & TAVR), Repair Procedure By Technique (Surgical, Balloon
More informationCommitted to Transforming the Treatment Paradigm for Migraine Prevention
June 14, 2018 Committed to Transforming the Treatment Paradigm for Migraine Prevention September 6, 2018 Forward-Looking Statements This presentation and the accompanying commentary contains certain forward-looking
More information34 th Annual J.P. Morgan Healthcare Conference
JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains
More informationInvestor Presentation. Q October 26, 2017
Investor Presentation Q1 2018 October 26, 2017 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private
More informationAugust 7, Q Financial Results
August 7, 2018 Q2 2018 Financial Results 1 Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationA world leader in allergy immunotherapy
A world leader in allergy immunotherapy Investor Relations presentation June 2017 1 I Investor Relations presentation I June 2017 ALK: Towards redefining treatment of severe allergies The commercial leader
More informationFORM8-K HILLENBRAND,INC.
UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015
More information27 th Annual J.P. Morgan Healthcare Conference. January 13, 2009
27 th Annual J.P. Morgan Healthcare Conference January 13, 2009 1 Forward Looking Statements This presentation and any subsequent Q&A may contain forward-looking statements, including with respect to:»
More informationMyriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016
Myriad Genetics Fiscal First-Quarter 2017 Earnings Call 11/01/2016 1 Forward Looking Statements Forward Looking Statements Some of the information presented here today may contain projections or other
More informationThe SAPIEN 3 TAVI Advantage
Edwards SAPIEN 3 Valve The SAPIEN 3 TAVI Advantage... The SAPIEN 3 TAVI Advantage The clear choice for your patients and your TAVI program Advanced valve and system designed to simplify procedures Consistent
More informationPatrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation
Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationOBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss
OBALON THERAPEUTICS, INC. (OBLN) The first and only FDA-approved swallowable, gas-filled intragastric balloon for weight loss Forward looking statements Except for statements of historical fact, information
More informationCowen Investor Conference March confidently live life with ease
Cowen Investor Conference March 2018 confidently live life with ease Forward-Looking Statements This presentation contains certain forward-looking statements that involve risks and uncertainties that could
More informationIndustry Research by Koncept Analytics
Industry Research by Koncept Analytics Global Transcatheter Mitral Valve Repair & Replacement (TMVR) Market: Industry Analysis & Outlook ----------------------------------------- (2018-2022) March 2018
More information2018 Bank of America Merrill Lynch Healthcare Conference
CHANGING THE COURSE OF HUMAN HEALTH THROUGH BOLD PURSUITS IN SCIENCE 2018 Bank of America Merrill Lynch Healthcare Conference May 16, 2018 Forward-Looking Statements and Adjusted Financial Information
More informationNovember 2, Q Financial Results
November 2, 2017 Q3 2017 Financial Results Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Steve Kanes, M.D., Ph.D., Chief Medical Officer
More informationForward Looking Information
Vital Signs, Inc. Forward Looking Information Except for historical information discussed, the statements made today are forward-looking statements that involve risks and uncertainties. Investors are cautioned
More informationInvestor Presentation. Q May 21, 2018
Investor Presentation Q3 2018 May 21, 2018 Safe Harbor Statement Statements contained in this presentation that are not historical facts are forwardlooking statements as contemplated by the Private Securities
More informationIncrease in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) H revenues and results - 24 July 2014
Increase in revenues in line with full-year targets (+1.2%) Very strong growth of Oralair exc. USA (+26%) ( ) H1 2014 revenues and results - 24 July 2014 Forward-looking statement This presentation contains
More informationClovis Oncology Announces Q Operating Results and Corporate Update. November 3, :05 PM ET
Clovis Oncology Announces Q3 2016 Operating Results and Corporate Update November 3, 2016 4:05 PM ET Rucaparib New Drug Application (NDA) accepted for Priority Review in the treatment of advanced BRCA-mutant
More informationEstablishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS
Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T H E P A R T N E R T R
More informationCowen Healthcare Conference
Cowen Healthcare Conference Shire plc March 9, 2010 Michael Cola President, Specialty Pharmaceuticals Our purpose We enable people with life-altering conditions to lead better lives 1 THE SAFE HARBOR STATEMENT
More informationIgor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School
Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of
More informationMyriad Genetics Corporate Presentation 6/4/13
Myriad Genetics Corporate Presentation 6/4/13 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events
More informationVisionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics
Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce
More informationForward-Looking Statements
Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.
More informationPhotocure ASA Executing the Strategy
Photocure ASA Executing the Strategy NOVEMBER 2012 ERIK DAHL, CFO KATHLEEN DEARDORFF, COO Disclaimer The information included in this Presentation contains certain forward-looking statements that address
More informationDonald E. Bobo, Jr. Corporate Vice President, Heart Valve Therapy. Surgical Heart Valve Therapy
Surgical Heart Valve Therapy Donald E. Bobo, Jr. Corporate Vice President, Heart Valve Therapy Celebrating 50 Years of Partnership - Leading 4 Generations of Heart Valve Innovation Mechanical Era Starr-Edwards
More informationSlide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes
Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with
More informationALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT
ALLERGAN TO ACQUIRE ZELTIQ FOR $2.47B BEST-IN-CLASS COMPANY IN FAST GROWING BODY CONTOURING SEGMENT ALLERGAN CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Statements contained in this presentation
More informationCOMPANY OVERVIEW. April 26, 2018
COMPANY OVERVIEW April 26, 2018 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationMyriad Genetics Corporate Presentation 06/13/2018
Myriad Genetics Corporate Presentation 06/13/2018 Copyright 2016 2018 Myriad Genetics, Inc., all rights reserved. www.myriad.com. 1 Forward Looking Statements Some of the information presented here today
More informationGlobal Transcatheter Mitral Valve Repair and Replacement (TMVR) Market: Analysis By Region, By Country: Opportunities and Forecast ( )
Global Transcatheter Mitral Valve Repair and Replacement (TMVR) Market: Analysis By Region, By Country: Opportunities and Forecast (2017-2022) By Region- North America, Europe, APAC and RoW By Country
More information37 th Annual J.P. Morgan Healthcare Conference. January 9, 2019
37 th Annual J.P. Morgan Healthcare Conference January 9, 2019 Forward Looking Statement This presentation includes forward-looking statements. All statements, other than statements of historical facts,
More informationMerrill Lynch conference. Matthew Emmens, CEO Shire plc September 20, 2007
Merrill Lynch conference Matthew Emmens, CEO Shire plc September 20, 2007 THE SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 Statements included herein that are not historical
More informationInvestor Presentation
Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities
More informationSlide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO
Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission
More informationHyundai Motor Company 1 st Quarter 2011 Business Results. April 28, 2011
Hyundai Motor Company 1 st Quarter 2011 Business Results April 28, 2011 Cautionary Statement with Respect to Forward-Looking Statements In the presentation that follows and in related comments by Hyundai
More informationFebruary 23, Q4 and Year-End 2016 Financial Results
February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,
More informationStraumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010
Media release Straumann reports 4% growth in local currencies (l.c.) in the first nine months of 2010 Growth driven by implant volumes, lifted by Bone Level implant range and Roxolid Third quarter (+3%
More informationSumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical
For immediate release November 25, 2004 Sumitomo Pharmaceuticals reaches a basic agreement to merge with Dainippon Pharmaceutical Sumitomo Chemical Co., Ltd. announced today that its subsidiary, Sumitomo
More informationUpdate on Transcatheter Mitral Valve Repair and Replacment
Update on Transcatheter Mitral Valve Repair and Replacment Vinod H. Thourani, MD Professor of Surgery Chair, Department of Cardiac Surgery Medstar Heart and Vascular Washington Hospital Center Georgetown
More informationMy Choice For Percutaneous Mitral Valve Replacement. Jose Luis Navia, MD.
My Choice For Percutaneous Mitral Valve Replacement Jose Luis Navia, MD. Disclosure Edwards Lifescienses St. Jude Medical MAQUET NaviGate Consultant, Investigator Consultant, Investigator Consultant, Investigator
More information- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes
Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen Wound Conforming Gel Matrix with Three Dosage Options - Plans Commercial Launch of three dosing options
More information4 th Quarter 2017 Earnings Review & Investor Update
4 th Quarter 2017 Earnings Review & Investor Update February 5, 2018 1 Forward-Looking Information This presentation contains statements about the Company s future plans and prospects that constitute forward-looking
More informationSlide 1. Investor presentation. London 5 February 2019
Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation
More informationWalgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs
Walgreen Co. Reports Second Quarter 2010 Earnings Per Diluted Share of 68 Cents; Results Include 2 Cents Per Diluted Share of Restructuring Costs Second quarter sales up 3.1 percent to record $17.0 billion
More informationMichael L. Levitz Chief Financial Officer. November 15, 2017 Investor Presentation
Michael L. Levitz Chief Financial Officer November 15, 2017 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,
More informationInvestor Presentation June 2012 NASDAQ: CEMI
Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act
More informationCell Therapy. Cytori Corporate Presentation January 2012
Cytori Corporate Presentation January 2012 Safe Harbor This presentation may contain certain forward-looking statements. All statements, other than statements of historical fact, that address activities,
More informationAstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance. Becoming Global Leaders In Diabetes
AstraZeneca to Acquire Bristol- Myers Squibb Share of Global Diabetes Alliance Becoming Global Leaders In Diabetes 19th December 2013 Cautionary Statement Regarding Forward-Looking Statements In order,
More informationCOMPANY OVERVIEW. July 30, 2018
COMPANY OVERVIEW July 30, 2018 SAFE HARBOR & NON-GAAP FINANCIAL MEASURES Forward Looking Statements Certain statements in this presentation constitute forward-looking statements, including, without limitation,
More informationSlide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO
Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company
More information